Overview Dividends

(JNJ) Johnson & Johnson - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4781601046

Pharmaceuticals, Devices, Lenses, Orthopedics, Surgery

Pharmaceuticals
Market Cap in USD: 500,603m

IPO / Inception: 1944-09-24
Return 12m vs S&P 500: 25.7%

EPS (Earnings per Share)

EPS CAGR: 7.57%
EPS Trend: 22.0%

Last SUE: 0.55
Qual. Beats: 0

Revenue

Rev. CAGR: -0.88%
Rev. Trend: -24.3%

Last SUE: 0.51
Qual. Beats: 0

Dividends

Dividend Yield	2.48%
Yield on Cost 5y	3.87%
Yield CAGR 5y	5.39%
Payout Consistency	96.4%
Payout Ratio	49.5%

Risk via 5d forecast
Volatility	17.1%
Value at Risk 5%th	26.6%
Relative Tail Risk	-5.49%

Reward TTM
Sharpe Ratio	1.85
Alpha	42.35
CAGR/Max DD	0.51

Character TTM
Hurst Exponent	0.475
Beta	0.057
Beta Downside	0.061

Drawdowns 3y
Max DD	17.43%
Mean DD	8.06%
Median DD	8.35%

Description: JNJ Johnson & Johnson December 02, 2025

Johnson & Johnson (NYSE: JNJ) operates globally in two main segments-Innovative Medicine, which covers a broad therapeutic portfolio from immunology to oncology, and MedTech, which supplies advanced devices for cardiovascular, orthopaedic, surgical, and eye-care markets. The company distributes its products through a mix of wholesalers, hospitals, retailers, and direct clinical channels, leveraging a legacy brand that dates back to its 1886 founding in New Brunswick, New Jersey.

Key data points to watch: (1) Q3 2023 revenue of $15.2 billion, with the Innovative Medicine segment contributing roughly 57 % of total sales; (2) a trailing twelve-month operating margin near 30 % and a dividend yield around 2.8 %, reflecting strong cash generation; and (3) pipeline drivers such as Stelara (psoriasis/IBD) and Darzalex (multiple myeloma) that together could add $5–7 billion in incremental sales over the next five years, assuming successful regulatory outcomes and market uptake. Macro-level, U.S. healthcare spending is projected to grow at a 5 % CAGR, bolstering demand for both prescription drugs and medical devices, while aging demographics increase exposure to JNJ’s orthopaedic and cardiovascular franchises.

If you want a data-rich, model-ready overview of JNJ’s valuation and risk factors, a quick look at ValueRay’s analyst toolkit can be a useful next step.

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (25.12b TTM) > 0 and > 6% of Revenue (6% = 5.53b TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA -1.05pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 4.06% (prev 1.70%; Δ 2.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 24.20b <= Net Income 25.12b (YES >=105%, WARN >=100%)

Net Debt (27.56b) to EBITDA (39.56b) ratio: 0.70 <= 3.0 (WARN <= 3.5)

Current Ratio 1.07 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (2.43b) change vs 12m ago 0.03% (target <= -2.0% for YES)

Gross Margin 68.08% (prev 69.05%; Δ -0.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 49.66% (prev 49.19%; Δ 0.47pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 48.23 (EBITDA TTM 39.56b / Interest Expense TTM 667.0m) >= 6 (WARN >= 3)

Altman Z'' 5.56

(A) 0.02 = (Total Current Assets 54.61b - Total Current Liabilities 50.87b) / Total Assets 192.82b

(B) 0.87 = Retained Earnings (Balance) 167.28b / Total Assets 192.82b

warn (B) unusual magnitude: 0.87 — check mapping/units

(D) 1.37 = Book Value of Equity 155.16b / Total Liabilities 113.54b

Total Rating: 5.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 74.19

1. Piotroski 3.50pt

2. FCF Yield 3.52%

3. FCF Margin 20.69%

4. Debt/Equity 0.58

5. Debt/Ebitda 0.70

6. ROIC - WACC (= 12.25)%

7. RoE 32.69%

8. Rev. Trend -24.27%

9. EPS Trend 22.03%

What is the price of JNJ shares?

As of December 29, 2025, the stock is trading at USD 207.63 with a total of 2,316,560 shares traded.
Over the past week, the price has changed by +0.15%, over one month by +0.34%, over three months by +15.05% and over the past year by +49.28%.

Is JNJ a buy, sell or hold?

Johnson & Johnson has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold JNJ.

Strong Buy: 7
Buy: 4
Hold: 13
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the JNJ price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	209.3	0.8%
Analysts Target Price	209.3	0.8%
ValueRay Target Price	236.4	13.9%

JNJ Fundamental Data Overview December 27, 2025

Market Cap USD = 500.60b (500.60b USD * 1.0 USD.USD)
P/E Trailing = 20.0754
P/E Forward = 18.0832
P/S = 5.4325
P/B = 6.3146
P/EG = 1.1222
Beta = 0.349
Revenue TTM = 92.15b USD
EBIT TTM = 32.17b USD
EBITDA TTM = 39.56b USD
Long Term Debt = 39.41b USD (from longTermDebt, last quarter)
Short Term Debt = 6.39b USD (from shortTermDebt, last quarter)
Debt = 45.80b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 27.56b USD (from netDebt column, last quarter)
Enterprise Value = 541.10b USD (500.60b + Debt 45.80b - CCE 5.30b)
Interest Coverage Ratio = 48.23 (Ebit TTM 32.17b / Interest Expense TTM 667.0m)
FCF Yield = 3.52% (FCF TTM 19.06b / Enterprise Value 541.10b)
FCF Margin = 20.69% (FCF TTM 19.06b / Revenue TTM 92.15b)
Net Margin = 27.26% (Net Income TTM 25.12b / Revenue TTM 92.15b)
Gross Margin = 68.08% ((Revenue TTM 92.15b - Cost of Revenue TTM 29.42b) / Revenue TTM)
Gross Margin QoQ = 69.56% (prev 67.87%)
Tobins Q-Ratio = 2.81 (Enterprise Value 541.10b / Total Assets 192.82b)
Interest Expense / Debt = 0.04% (Interest Expense 18.0m / Debt 45.80b)
Taxrate = 31.24% (2.34b / 7.49b)
NOPAT = 22.12b (EBIT 32.17b * (1 - 31.24%))
Current Ratio = 1.07 (Total Current Assets 54.61b / Total Current Liabilities 50.87b)
Debt / Equity = 0.58 (Debt 45.80b / totalStockholderEquity, last quarter 79.28b)
Debt / EBITDA = 0.70 (Net Debt 27.56b / EBITDA 39.56b)
Debt / FCF = 1.45 (Net Debt 27.56b / FCF TTM 19.06b)
Total Stockholder Equity = 76.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.03% (Net Income 25.12b / Total Assets 192.82b)
RoE = 32.69% (Net Income TTM 25.12b / Total Stockholder Equity 76.84b)
RoCE = 27.67% (EBIT 32.17b / Capital Employed (Equity 76.84b + L.T.Debt 39.41b))
RoIC = 17.95% (NOPAT 22.12b / Invested Capital 123.20b)
WACC = 5.70% (E(500.60b)/V(546.40b) * Re(6.22%) + D(45.80b)/V(546.40b) * Rd(0.04%) * (1-Tc(0.31)))
Discount Rate = 6.22% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.04%
[DCF Debug] Terminal Value 78.16% ; FCFE base≈19.24b ; Y1≈19.07b ; Y5≈19.88b
Fair Price DCF = 146.2 (DCF Value 352.28b / Shares Outstanding 2.41b; 5y FCF grow -1.62% → 3.0% )
EPS Correlation: 22.03 | EPS CAGR: 7.57% | SUE: 0.55 | # QB: 0
Revenue Correlation: -24.27 | Revenue CAGR: -0.88% | SUE: 0.51 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.75 | Chg30d=-0.007 | Revisions Net=-1 | Analysts=13
EPS next Year (2026-12-31): EPS=11.54 | Chg30d=+0.036 | Revisions Net=+9 | Growth EPS=+6.2% | Growth Revenue=+5.1%

Additional Sources for JNJ Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle